Karos Pharmaceuticals Report issue

For profit Phase 1
Founded: New Haven CT United States (2009)
Status: Acquired by Roivant Sciences, Inc. (2017) → now Sumitomo Dainippon (2005)

Organization Overview

First Clinical Trial
2015
NCT02746237
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 1 Trials (1)

rodatristat ethyl (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypertension (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1